{"name": "terlipressin", "category": "drug", "content": "Terlipressin, sold under the brand name Terlivaz  among others, is an analogue of vasopressin used as a vasoactive drug in the management of low blood pressure.  It has been found to be effective when norepinephrine does not help. Terlipressin is a vasopressin receptor agonist. Terlipressin was approved for medical use in the United States in 2022. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.   == Medical uses == Terlipressin is indicated to improve kidney function in adults with hepatorenal syndrome with rapid reduction in kidney function. Indications for use include norepinephrine-resistant septic shock although, 2021 Surviving Sepsis Guidelines recommend against its use for adults with septic shock and hepatorenal syndrome. In addition, it is used to treat bleeding esophageal varices.   == Contraindications == Terlipressin is contraindicated in people experiencing hypoxia or worsening respiratory symptoms and in people with ongoing coronary, peripheral or mesenteric ischemia. Terlipressin may cause fetal harm when used during pregnancy.   == Society and culture == Terlipressin is available in United States, New Zealand, Australia, the European Union, India, Pakistan & UAE. It is sold under various brand names including Glypressin and Terlivaz.   == References ==   == External links == \"Terlipressin\". Drug Information Portal. U.S. National Library of Medicine."}